Neuroleptic malignant syndrome in juvenile neuronal ceroid lipofuscinosis associated with low-dose risperidone therapy.
We present a patient with juvenile neuronal ceroid lipofuscinosis who developed a neuroleptic malignant syndrome when treated for hallucinations with a very low dose of risperidone, an atypical neuroleptic medication with usually few extrapyramidal side-effects. The loss of dopaminergic neurons in this condition may make these patients more vulnerable to this severe adverse effect.
Vercammen
L
L
Department of Pediatrics, University Hospital Gasthuisberg, Catholic University Leuven, Leuven, Belgium.
Buyse
G M
GM
Proost
J E F
JE
Van Hove
J L K
JL
D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D003402:Creatine Kinase / Q000097:blood; D004298:Dopamine / Q000502:physiology; D005260:Female; D005334:Fever / Q000150:complications; D006212:Hallucinations / Q000188:drug therapy; D006801:Humans; D008607:Intellectual Disability; D009459:Neuroleptic Malignant Syndrome / Q000150:complications*; D009472:Neuronal Ceroid-Lipofuscinoses / Q000150:complications* / Q000523:psychology; D018967:Risperidone / Q000009:adverse effects* / Q000627:therapeutic use
D014150:Antipsychotic Agents; D003402:Creatine Kinase; D018967:Risperidone; D004298:Dopamine